Sign In
Buy CTLT
$63.49
+0 (+0%)
At Close: Mar 14, 2025
Catalent (CTLT) Sees Hammer Chart Pattern: Time to Buy?
07:11am, Monday, 15'th Mar 2021
Catalent (CTLT) has been struggling lately, but the selling pressure may be coming to an end soon
Catalent, Inc. to Present at the SVB Leerink 10th Annual Global Healthcare Conference
04:15pm, Friday, 19'th Feb 2021
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gen
USNA vs. CTLT: Which Stock Is the Better Value Option?
12:52pm, Thursday, 11'th Feb 2021
USNA vs. CTLT: Which Stock Is the Better Value Option?
Catalent Announces Upsizing and Pricing of Private Offering of Senior Unsecured Notes Due 2029
04:49pm, Wednesday, 10'th Feb 2021
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (“Catalent”) (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biolog
Catalent Announces Launch of Private Offering of $475 Million of Senior Unsecured Notes Due 2029
07:44am, Wednesday, 10'th Feb 2021
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (“Catalent”) (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biolog
Catalent, Inc. (CTLT) CEO John Chiminski on Q2 2021 Results - Earnings Call Transcript
03:36pm, Tuesday, 02'nd Feb 2021
Catalent, Inc. (CTLT) CEO John Chiminski on Q2 2021 Results - Earnings Call Transcript
Catalent: Q2 Earnings Insights
07:37am, Tuesday, 02'nd Feb 2021
Shares of Catalent (NYSE:CTLT) moved higher by 1.2% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 40.00% year over year to $0.63, which beat
Catalent, Inc. Reports Second Quarter Fiscal 2021 Results
07:15am, Tuesday, 02'nd Feb 2021
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gen
Catalent, Inc. Announces Second Quarter Fiscal Year 2021 Earnings Conference Webcast
08:45am, Wednesday, 20'th Jan 2021
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene and cel
Why Catalent (CTLT) is Poised to Beat Earnings Estimates Again
01:32pm, Monday, 18'th Jan 2021
Catalent (CTLT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
4 Winners Highlight Top Jefferies Growth Stocks to Buy in 2021
08:37am, Monday, 11'th Jan 2021
Increasingly, the Wall Street firms we cover are starting to agree that while the future for the U.S.
Looking for a Growth Stock? 3 Reasons Why Catalent (CTLT) is a Solid Choice
01:32pm, Tuesday, 05'th Jan 2021
Catalent (CTLT) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Analysts' Top Health Care Stocks to Buy Could Be Big 2021 Winners
10:25am, Tuesday, 29'th Dec 2020
As is the case every year, the major Wall Street firms we cover here at 24/7 Wall St.
Here's Why Catalent (CTLT) is a Great Momentum Stock to Buy
12:48pm, Thursday, 24'th Dec 2020
Does Catalent (CTLT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Catalent Joins Rank Of Stocks With 95-Plus Composite Rating
10:54am, Friday, 11'th Dec 2020
On Friday, Catalent got an upgrade for its IBD SmartSelect Composite Rating from 94 to 96. The post Catalent Joins Rank Of Stocks With 95-Plus Composite Rating appeared first on Investor's Business Da
